These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23307059)

  • 1. Anaplastic lymphoma kinase status in rhabdomyosarcomas.
    Yoshida A; Shibata T; Wakai S; Ushiku T; Tsuta K; Fukayama M; Makimoto A; Furuta K; Tsuda H
    Mod Pathol; 2013 Jun; 26(6):772-81. PubMed ID: 23307059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK protein expression in rhabdomyosarcomas.
    Pillay K; Govender D; Chetty R
    Histopathology; 2002 Nov; 41(5):461-7. PubMed ID: 12405914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
    Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
    J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.
    Le Loarer F; Cleven AHG; Bouvier C; Castex MP; Romagosa C; Moreau A; Salas S; Bonhomme B; Gomez-Brouchet A; Laurent C; Le Guellec S; Audard V; Giraud A; Ramos-Oliver I; Cleton-Jansen AM; Savci-Heijink DC; Kroon HM; Baud J; Pissaloux D; Pierron G; Sherwood A; Coindre JM; Bovée JVMG; Larousserie F; Tirode F
    Mod Pathol; 2020 Mar; 33(3):404-419. PubMed ID: 31383960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.
    Bridge JA; Liu J; Qualman SJ; Suijkerbuijk R; Wenger G; Zhang J; Wan X; Baker KS; Sorensen P; Barr FG
    Genes Chromosomes Cancer; 2002 Mar; 33(3):310-21. PubMed ID: 11807989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histology-specific expression of a DNA repair protein in pediatric rhabdomyosarcomas.
    Thomson B; Tritt R; Davis M; Kelley MR
    J Pediatr Hematol Oncol; 2001 May; 23(4):234-9. PubMed ID: 11846302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma.
    Cen L; Arnoczky KJ; Hsieh FC; Lin HJ; Qualman SJ; Yu S; Xiang H; Lin J
    Mod Pathol; 2007 Sep; 20(9):936-46. PubMed ID: 17585318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
    Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
    Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions.
    Busam KJ; Kutzner H; Cerroni L; Wiesner T
    Am J Surg Pathol; 2014 Jul; 38(7):925-33. PubMed ID: 24698967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
    Schöffski P; Wozniak A; Leahy MG; Aamdal S; Rutkowski P; Bauer S; Richter S; Grünwald V; Debiec-Rychter M; Sciot R; Geoerger B; Marréaud S; Collette S; Nzokirantevye A; Strauss SJ
    Eur J Cancer; 2018 May; 94():156-167. PubMed ID: 29567632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases.
    Li XQ; Hisaoka M; Shi DR; Zhu XZ; Hashimoto H
    Hum Pathol; 2004 Jun; 35(6):711-21. PubMed ID: 15188137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.